Abstract
Treatment of unresectable malignant pleural mesothelioma in 2021: emerging standards in immunotherapy
Highlights
Treatment of unresectable malignant pleural mesothelioma (MPM) remains a challenging problem, and outcomes are most often disappointing
Two toxic deaths occurred in the bevacizumab arm, compared to 0 in the chemotherapy only group, and toxicity related treatment discontinuation was significantly higher in the bevacizumab arm (24.3% vs. 6.0%)
The success of several large-scale well-designed trials proves that ambitious clinical trials to answer urgent questions about the treatment of MPM are exigent but feasible, and there is reason to believe that outcomes for patients with MPM will continue to improve rapidly over the decade
Summary
Treatment of unresectable malignant pleural mesothelioma (MPM) remains a challenging problem, and outcomes are most often disappointing. Continued support of robust clinical research will be indispensable in integrating these advances into the evolving standard of care and addressing the ongoing unmet need for these patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
